• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

肾源性系统性纤维化与钆类对比剂：ESUR 对比剂安全委员会更新指南。

Nephrogenic systemic fibrosis and gadolinium-based contrast media: updated ESUR Contrast Medium Safety Committee guidelines.

机构信息

Department of Diagnostic Radiology 54E2, Copenhagen University Hospital Herlev, Herlev Ringvej 75, 2730 Herlev, Denmark.

出版信息

Eur Radiol. 2013 Feb;23(2):307-18. doi: 10.1007/s00330-012-2597-9. Epub 2012 Aug 4.

DOI:10.1007/s00330-012-2597-9
PMID:22865271
Abstract

PURPOSE

To update the guidelines of the Contrast Media Safety Committee (CMSC) of the European Society of Urogenital Radiology (ESUR) on nephrogenic systemic fibrosis and gadolinium-based contrast media.

AREAS COVERED

Topics reviewed include the history, clinical features and prevalence of nephrogenic systemic fibrosis and the current understanding of its pathophysiology. The risk factors for NSF are discussed and prophylactic measures are recommended. The stability of the different gadolinium-based contrast media and the potential long-term effects of gadolinium in the body have also been reviewed.

摘要

目的

更新欧洲泌尿生殖放射学会（ESUR）对比剂安全委员会（CMSC）关于肾源性系统性纤维化和钆基对比剂的指南。

涵盖领域

综述内容包括肾源性系统性纤维化的历史、临床特征和流行情况，以及目前对其病理生理学的理解。讨论了 NSF 的危险因素，并建议采取预防措施。还回顾了不同的钆基对比剂的稳定性以及体内的潜在长期的钆的影响。

相似文献

1
Nephrogenic systemic fibrosis and gadolinium-based contrast media: updated ESUR Contrast Medium Safety Committee guidelines.肾源性系统性纤维化与钆类对比剂：ESUR 对比剂安全委员会更新指南。
Eur Radiol. 2013 Feb;23(2):307-18. doi: 10.1007/s00330-012-2597-9. Epub 2012 Aug 4.
2
Nephrogenic systemic fibrosis: UK survey of the use of gadolinium-based contrast media.肾源性系统性纤维化：英国对钆类造影剂使用情况的调查。
Clin Radiol. 2010 Aug;65(8):636-41. doi: 10.1016/j.crad.2010.04.012. Epub 2010 Jun 11.
3
[Causal relationship between the use of gadolinium based contrast media and nephrogenic systemic fibrosis].钆基造影剂的使用与肾源性系统性纤维化之间的因果关系
Rev Med Chil. 2014 Dec;142(12):1565-74. doi: 10.4067/S0034-98872014001200010.
4
How to avoid nephrogenic systemic fibrosis: current guidelines in Europe and the United States.如何避免肾源性系统性纤维化：欧美现行指南
Radiol Clin North Am. 2009 Sep;47(5):871-5, vii. doi: 10.1016/j.rcl.2009.05.002.
5
Nephrogenic systemic fibrosis: a systemic fibrosing disease resulting from gadolinium exposure.肾源性系统性纤维化：一种由钆暴露引起的全身性纤维性疾病。
Best Pract Res Clin Rheumatol. 2012 Aug;26(4):489-503. doi: 10.1016/j.berh.2012.07.008.
6
Safety of magnetic resonance contrast media: a review with special focus on nephrogenic systemic fibrosis.磁共振造影剂的安全性：特别关注肾源性系统性纤维化的综述
Top Magn Reson Imaging. 2015 Feb;24(1):57-65. doi: 10.1097/RMR.0b013e3182a14e79.
7
Current status of nephrogenic systemic fibrosis.肾源性系统性纤维化的现状。
Clin Radiol. 2014 Jul;69(7):661-8. doi: 10.1016/j.crad.2014.01.003. Epub 2014 Feb 28.
8
Gadolinium and nephrogenic systemic fibrosis: an update.钆与肾源性系统性纤维化：最新进展
Pediatr Nephrol. 2014 Oct;29(10):1927-37. doi: 10.1007/s00467-013-2636-z. Epub 2013 Oct 22.
9
Minimizing risk of nephrogenic systemic fibrosis in cardiovascular magnetic resonance.尽量降低心血管磁共振成像中肾源性系统性纤维化的风险。
J Cardiovasc Magn Reson. 2012 May 20;14(1):31. doi: 10.1186/1532-429X-14-31.
10
Canadian Association of Radiologists national advisory on gadolinium administration and nephrogenic systemic fibrosis.加拿大放射学会关于钆给药与肾源性系统性纤维化的全国性咨询意见。
Can Assoc Radiol J. 2008 Dec;59(5):237-40.

引用本文的文献

1
Current Status and Future Aspects of Gadolinium Oxide Nanoparticles as Positive Magnetic Resonance Imaging Contrast Agents.氧化钆纳米颗粒作为阳性磁共振成像造影剂的现状与未来展望
Nanomaterials (Basel). 2025 Sep 1;15(17):1340. doi: 10.3390/nano15171340.
2
Gadolinium toxicity: mechanisms, clinical manifestations, and nanoparticle role.钆毒性：作用机制、临床表现及纳米颗粒的作用
Arch Toxicol. 2025 Jul 3. doi: 10.1007/s00204-025-04124-x.
3
Cationic fluorinated micelles for cell labeling and F-MR imaging.阳离子氟化物胶束用于细胞标记和 F-MR 成像。

本文引用的文献

1
Gadolinium-induced nephrogenic systemic fibrosis: the rise and fall of an iatrogenic disease.钆诱导的肾源性系统性纤维化：一种医源性疾病的兴衰。
Clin Kidney J. 2012 Feb;5(1):82-88. doi: 10.1093/ckj/sfr172.
2
Contrast induced nephropathy: updated ESUR Contrast Media Safety Committee guidelines.对比剂肾病：更新的 ESUR 对比剂安全委员会指南。
Eur Radiol. 2011 Dec;21(12):2527-41. doi: 10.1007/s00330-011-2225-0. Epub 2011 Aug 25.
3
Risk of nephrogenic systemic fibrosis in liver transplantation patients.肝移植患者发生肾源性系统性纤维化的风险。
Sci Rep. 2024 Sep 30;14(1):22613. doi: 10.1038/s41598-024-73511-8.
4
The use of intravascular contrast media in patients with impaired kidney function - joint clinical practice position statement of the Polish Society of Nephrology and the Polish Medical Society of Radiology.肾功能受损患者血管内造影剂的使用——波兰肾脏病学会和波兰放射医学学会联合临床实践立场声明
Pol J Radiol. 2024 Mar 21;89:e161-e171. doi: 10.5114/pjr.2024.136950. eCollection 2024.
5
Rational Design of Magnetic Nanoparticles as T-T Dual-Mode MRI Contrast Agents.作为 T1/T2 双模式 MRI 对比剂的磁性纳米粒子的合理设计。
Molecules. 2024 Mar 18;29(6):1352. doi: 10.3390/molecules29061352.
6
Lightweight preprocessing and template matching facilitate streamlined ischemic myocardial scar classification.轻量级预处理和模板匹配有助于简化缺血性心肌瘢痕分类。
J Med Imaging (Bellingham). 2024 Mar;11(2):024503. doi: 10.1117/1.JMI.11.2.024503. Epub 2024 Mar 21.
7
Accuracy of Noncontrast T2 SPACE in Active MS Cord Lesion Detection.非增强 T2 SPACE 在活动 MS 脊髓病灶检测中的准确性。
AJNR Am J Neuroradiol. 2023 Dec 11;44(12):1458-1463. doi: 10.3174/ajnr.A8060.
8
Assessment of myocardial injuries in ischaemic and non-ischaemic cardiomyopathies using magnetic resonance T1-rho mapping.采用磁共振 T1-ρ mapping 评估缺血性和非缺血性心肌病中的心肌损伤。
Eur Heart J Cardiovasc Imaging. 2024 Mar 27;25(4):548-557. doi: 10.1093/ehjci/jead319.
9
Cardiovascular magnetic resonance imaging for sequential assessment of cardiac fibrosis in mice: technical advancements and reverse translation.心血管磁共振成像用于小鼠心脏纤维化的序贯评估：技术进展和反向翻译。
Am J Physiol Heart Circ Physiol. 2024 Jan 1;326(1):H1-H24. doi: 10.1152/ajpheart.00437.2023. Epub 2023 Nov 3.
10
Peripheral arterial disease treatment planning using noninvasive and invasive imaging methods.使用非侵入性和侵入性成像方法进行外周动脉疾病治疗规划。
J Vasc Surg Cases Innov Tech. 2023 Aug 19;9(4):101263. doi: 10.1016/j.jvscit.2023.101263. eCollection 2023 Dec.
AJR Am J Roentgenol. 2011 Sep;197(3):658-62. doi: 10.2214/AJR.10.5976.
4
Nephrogenic systemic fibrosis: clinicopathological definition and workup recommendations.肾源性系统性纤维化：临床病理定义和检查建议。
J Am Acad Dermatol. 2011 Dec;65(6):1095-1106.e7. doi: 10.1016/j.jaad.2010.08.041. Epub 2011 Jul 2.
5
Nephrogenic systemic fibrosis is found only among gadolinium-exposed patients with renal insufficiency: a case-control study from Denmark.肾源性系统性纤维化仅见于接受钆暴露且肾功能不全的患者：来自丹麦的一项病例对照研究。
Br J Dermatol. 2011 Oct;165(4):828-36. doi: 10.1111/j.1365-2133.2011.10465.x.
6
Nephrogenic systemic fibrosis and gadolinium-based contrast agents.肾源性系统性纤维化与钆类对比剂。
Adv Chronic Kidney Dis. 2011 May;18(3):188-98. doi: 10.1053/j.ackd.2011.03.001.
7
Experimental studies investigating the pathophysiology of nephrogenic systemic fibrosis; what did we learn so far?探究肾源性系统性纤维化病理生理学的实验研究；我们目前了解到了什么？
Eur Radiol. 2011 Mar;21(3):496-500. doi: 10.1007/s00330-010-1951-z. Epub 2010 Sep 17.
8
Screening patients to assess renal function before administering gadolinium chelates: assessment of the Choyke questionnaire.在给钆螯合物前对患者进行肾功能筛查：Choyke 问卷评估。
AJR Am J Roentgenol. 2010 Aug;195(2):424-8. doi: 10.2214/AJR.09.3803.
9
The biodistribution of [153Gd]Gd-labeled magnetic resonance contrast agents in a transgenic mouse model of renal failure differs greatly from control mice.[153Gd]标记的磁共振对比剂在肾衰竭转基因小鼠模型中的生物分布与正常小鼠有很大差异。
Magn Reson Med. 2010 Nov;64(5):1274-80. doi: 10.1002/mrm.22553.
10
Nephrogenic systemic fibrosis: risk factors suggested from Japanese published cases.肾源性系统性纤维化：日本已发表病例提示的风险因素。
Br J Radiol. 2010 Jul;83(991):590-5. doi: 10.1259/bjr/17689538. Epub 2010 Apr 22.